PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-27.40%
Negative revenue growth while 4997.T stands at 19.25%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-30.39%
Negative gross profit growth while 4997.T is at 42.83%. Joel Greenblatt would examine cost competitiveness or demand decline.
-146.88%
Negative EBIT growth while 4997.T is at 738.96%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-162.90%
Negative operating income growth while 4997.T is at 738.96%. Joel Greenblatt would press for urgent turnaround measures.
-180.00%
Negative net income growth while 4997.T stands at 12716.67%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-180.00%
Negative EPS growth while 4997.T is at 12723.53%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-180.00%
Negative diluted EPS growth while 4997.T is at 12723.53%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
OCF growth of 9.59% while 4997.T is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
9.59%
FCF growth of 9.59% while 4997.T is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
-30.52%
Negative 10Y revenue/share CAGR while 4997.T stands at 168.50%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-6.70%
Negative 5Y CAGR while 4997.T stands at 69.73%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
1.86%
3Y revenue/share CAGR under 50% of 4997.T's 96.36%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-147.74%
Negative 10Y net income/share CAGR while 4997.T is at 6463.36%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1678.92%
Negative 5Y net income/share CAGR while 4997.T is 393.89%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-56.19%
Negative 3Y CAGR while 4997.T is 554.38%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
101.72%
10Y equity/share CAGR above 1.5x 4997.T's 66.81%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
48.01%
5Y equity/share CAGR above 1.5x 4997.T's 25.35%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
31.40%
3Y equity/share CAGR 1.25-1.5x 4997.T's 23.41%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.82%
Our AR growth while 4997.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
19.48%
Inventory growth well above 4997.T's 8.58%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.51%
Asset growth above 1.5x 4997.T's 4.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-0.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
32.76%
Debt growth far above 4997.T's 37.94%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
42.86%
R&D growth of 42.86% while 4997.T is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-0.46%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.